This trial is active, not recruiting.

Condition malignant melanoma
Treatment zelboraf
Phase phase 4
Target BRAF
Sponsor Hoffmann-La Roche
Start date October 2013
End date June 2015
Trial size 60 participants
Trial identifier NCT01898585, ML28711


This open-label, single-arm, multicenter study will assess the safety and efficacy of Zelboraf (vemurafenib) in patients with Braf V600 mutation positive metastatic melanoma. Patients will receive Zelboraf 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.

Primary Outcomes

Safety: Incidence of adverse events
time frame: 12 months

Secondary Outcomes

Overall response rate according to Response evaluation criteria in solid tumors (RECIST v1.1)
time frame: 12 months
Progression free survival
time frame: 12 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Adults patients >= 18 years of age - Patients with histologically confirmed metastatic melanoma (surgically incurable and unresectable stage IIIC or stage IV; AJCC) with documented BRAF V600 mutation determined by the cobas® BRAF V600 Mutation Test prior to administration of vemurafenib. Unresectable stage IIIC disease must have confirmation from a surgical oncologist - Patients with either measurable or non-measurable disease (RECIST Version 1.1) - Patients may or may not have received prior systemic therapy for metastatic melanoma - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 - Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma - Adequate hematological, renal, and liver function - Negative serum pregnancy test at screening - Fertile men and women must use an effective form of contraception during the study and for at least 6 months after completion of the study Exclusion Criteria: - Evidence of symptomatic CNS lesions as determined by the investigator, use of steroid or anti-seizure medication for treatment of brain metastases prior to the first administration of vemurafenib - Patients with previous malignancies (other than melanoma) within the past 2 years except patients with treated and controlled basal or squamous cell carcinoma (SCC) of the skin or carcinoma in-situ of the cervix. - Concurrent administration of any anti-cancer therapies (e.g. chemotherapy, other targeted therapy, experimental drug, etc.) other than those administered in this study - Known hypersensitivity to vemurafenib or another BRAF inhibitor - Pregnant or lactating women - Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption. - Any of the following within the 6 months prior to the first vemurafenib administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischaemic attack, pulmonary embolism, hypertension not adequately controlled by current medications.

Additional Information

Official title An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.
Trial information was received from ClinicalTrials.gov and was last updated in May 2015.
Information provided to ClinicalTrials.gov by Hoffmann-La Roche.